SHANGHAI, China I March 11, 2024 I Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present its next generation ADC platform IDDC™ and the latest study results of multiple novel ADCs (9MW2821, 7MW3711, 9MW2921) developed based on this platform as poster presentation at the 14th World ADC London from March 12-15, 2024 local time.

The World ADC Event Series is the largest academic event in the global ADC field.

Poster Presentation

Poster Title: Mtoxin™ Payload Applied in IDDC™ ADC Platform Significant Increases Therapeutic Index and Overcome MultiDrug Resistance in Various Tumor
Booth No.: 26

About the next generation ADC platform IDDC™

IDDC™ is a next generation ADC site-specific conjugation technology platform independently developed by Mabwell, consisting of multiple systematic core patented technologies including the site-specific conjugation process DARfinity™, the site-specific linker IDconnect™, the novel payload Mtoxin™, and the conditional release structure LysOnly™. The next generation ADCs developed based on the above systematic patented technologies have better structural uniformity, quality stability, efficacy, and tolerability.

The IDDC™ platform has already been validated in multiple drugs under study. It is anticipated that more ADCs based on this platform will enter the clinical development stage in the future.

9MW2821 – novel Nectin-4-targeting ADC:
Mabwell is the first Chinese enterprise to advance 9MW2821 into Phase 3 clinical trials for the treatment of urothelial carcinoma, making it the second globally in terms of progress; 9MW2821 is also the first therapeutic drug in the world with the same target to disclose clinical efficacy data for indications of cervical cancer and esophageal carcinoma. 

7MW3711 – novel B7-H3-targeting ADC:
Clinical trials have been conducted for 7MW3711 for the indication of advanced solid tumors in China and it has received FDA approval to conduct clinical trials for patients with advanced malignant solid tumors.

9MW2921 – novel Trop-2-targeting ADC:
Clinical trials have been conducted for 9MW2921 for the indication of advanced solid tumors in China.

About Mabwell

Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with the entire value chain of the pharmaceutical industry. We provide more effective and accessible therapy and innovative medicines to fulfill global medical needs. Since 2017, an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation was established. Mabwell has 14 pipeline products in different stages based on a world-class and state-of-the-art R&D engine, including 10 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of oncology, auto-immune diseases, metabolic disorders, ophthalmologic diseases and infectious diseases, etc. Of these, 2 products have been approved and commercialized, 2 products have been filed for MA approval, 3 products are in pivotal trials. We have also undertaken 1 national major scientific and technological special project for “Significant New Drugs Development”, 2 projects for National Key R&D Programmes, and multiple provincial and municipal science and technological innovation projects. Mabwell’s Taizhou factory possesses robust in-house manufacturing capability compliant with international GMP standards regulated by the NMPA, FDA and EMA, and has passed the EU QP Audit. The large-scale manufacturing base located in Shanghai is under construction. Our mission is “Explore Life, Benefit Health” and our vision is “Innovation, from ideas to reality”. For more information, please visit

SOURCE: Mabwell